The science

The Radnost ^TM prognostic tool reveals the extent to which any solid tumour of any cancer type will respond to radiation treatment. This is achieved by using an apex metabolic predictor , and its cellular associations with normal metabolic products.

Detecting high levels of the metabolic predictor will mark a tumour as being more radio-resistant, whereas low levels will indicate a tumour at the radio-sensitive end of the spectrum. Importantly, after diagnosis, patients can quickly receive the most relevant treatment using a customised and specific treatment plan.

Learn more

 

The Technology

High-income countries routinely use advanced patient imaging equipment and radiation infrastructure such as IMRT, brachytherapy, GammaKnife and Proton Beam. Access to such tools is now increasing in frequency across the world. Our central processing laboratory uses sophisticated instrumentation and know how to provide clinicians with a Radnost™ score.

This score is then translated into practical patient-centric information for both medical and radiation oncologists, equipping them with knowledge to offer precision medicine enabling life-changing clinical decisions. Leveraging the universality of radiation behaviour, this technology can be utilised in conjunction with any current form of radiation treatment such as external beam radiation therapy, brachytherapy or more specialised instrumentation such as GammaKnife and Proton Beam.

Learn more

Cartography

The Radnost™ portfolio of cancer tests have extraordinary power and integrative potential, previously unseen in this field. The atomic cartography for specific element distribution within tumours can be overlaid with additional atomic maps from other labelled entities, such as drug targets, antibodies, immune cells and the distribution of biomarkers

This results in a ground-breaking multi-level cartographic output, capable of integrating all radiation data with other clinically significant treatment methods. Using automated image scanning technology and machine learning algorithms to combine this information, clinicians will now benefit from unprecedented insight into the properties of each specific tumour.

Learn more

 

Instrumentation

The powerful Radnost™ portfolio of cancer tests is based on state-of-the-art laser-based Mass Spectrometry and sophisticated data imaging.

This analytical technology produces detailed high-resolution maps of atomic distributions. The Radnost™ methodology then processes the tumour to produce a Radnost™ score for clinical use.

Learn more

Benefits

Radnost™ enables all patients with radio-sensitive tumours to benefit from radiation therapy, while those with highly resistant tumours can be assessed more specifically for alternative treatment options in a customised patient treatment program.

Radnost™ is the apex predictor for radiation treatments.

Many cancers prove resistant to radiation treatment. Some patients may die within months, while others with the same tumour type and equivalent radiation therapy treatment go on to survive for many years. To determine why some tumours respond to radiation treatment while others return, requires a new, non-traditional approach to oncology.

 

Why Radnost™ matters

Atomic Oncology has the capability to measure  distributions of specific elements significant in tissue sections of all solid tumour types as metabolic predictors of radiosensitivity, providing clinicians with a precise determination of expected radio-responsiveness and therefore greater insight into their patient outcomes. Our unique data provides patient-specific 3D maps that detail the spatial metallomic variability of cancer cells and their supporting stroma. These maps have fundamental and far-reaching clinical implications. For the first time, Radnost™ tumour data will lead the way to precise and specific radiation dosage, meaning an improved treatment experience for the individual, and more successful patient outcomes.